GlassScriptPhysician profile
Michael Spezia
NPI 1316928369
$26,413.96
in general payments reported to CMS, 2019-2025
57 companies · $3,766 in 2025
The $3,766 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,082 · 2020: $3,032 · 2021: $3,237 · 2022: $3,542 · 2023: $4,293 · 2024: $3,463 · 2025: $3,766.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,416.92 |
| Education | $104.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $5,952.47 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,992.05 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $1,798.18 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $1,649.19 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $1,527.76 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,369.30 | 2020-2025 | Rexulti, Jynarque |
| Lilly USA, LLC | $1,289.30 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Merck Sharp & Dohme LLC | $1,033.84 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Astellas Pharma US INC | $640.77 | 2019-2025 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $602.83 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $552.51 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $546.75 | 2019-2023 | Xarelto |
| Biohaven Pharmaceutical Holding Company LTD. | $524.14 | 2022 | |
| Amarin Pharma, INC. | $520.31 | 2019-2021 | |
| Dexcom, INC. | $447.05 | 2021-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Spezia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.